je.st
news
Tag: announces
Goss announces new partnership and strategy at drupa
2016-06-01 18:22:00| Label and Narrow Web Breaking News
Goss also highlighted its continued and renewed focus on its Lifetime Support services.
Tags: strategy
partnership
announces
goss
USTR Announces Sugar Tariff-Rate Quotas for Fiscal Year 2017
2016-06-01 10:00:00| Expeditors Newsflash - Americas Edition
Expeditors Newsflash - Americas Edition
Tags: year
fiscal
sugar
announces
Pembina Pipeline Corporation Announces New Duvernay Infrastructure And Agreements
2016-06-01 07:54:19| chemicalonline Home Page
Pembina Pipeline Corporation ("Pembina" or the "Company") (TSX: PPL; NYSE: PBA) announced today that it has entered into agreements with a multinational, investment grade customer to construct associated infrastructure relating to the Company's previously announced 100 million cubic feet per day ("MMcf/d") shallow cut gas plant, Duvernay I ("Duvernay I")
Tags: corporation
infrastructure
agreements
announces
Cerulean Announces First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
2016-06-01 06:09:24| drugdiscoveryonline Home Page
Cerulean Pharma Inc., a clinical-stage company developing nanoparticle-drug conjugates (NDCs), recently announced that the first patient has been dosed in an open-label, single center Phase 1/2 clinical trial of its lead NDC candidate, CRLX101, in combination with LYNPARZA (olaparib) in patients with advanced solid tumors
Tags: with
trial
combination
phase
Syros Pharmaceuticals Announces FDA Acceptance Of IND To Advance SY-1425 Into Phase 2 Clinical Trial
2016-06-01 04:49:19| drugdiscoveryonline Home Page
Syros Pharmaceuticals recently announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s Investigational New Drug (IND) application to advance its lead drug candidate, SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, into a Phase 2 clinical trial in genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia (AML) and relapsed high-risk myelodysplastic syndrome (MDS) identified through its platform
Tags: trial
advance
phase
acceptance
Sites : [470] [471] [472] [473] [474] [475] [476] [477] [478] [479] [480] [481] [482] [483] [484] [485] [486] [487] [488] [489] next »